E
CDTX

Ergoteles’s Cidara Therapeutics CDTX Stock Holding History

Ergoteles’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-8,004
Closed -$359K – 1268
2021
Q3 		$359K Sell
8,004
-146
-2% -$5.55K 0.01% 721
2021
Q2 		$329K Buy
+8,150
New +$345K 0.01% 1028

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Ergoteles's CDTX Position: Q4 2021 in Review

Ergoteles sold out of Cidara Therapeutics (CDTX) in Q4 2021, closing a stake of 8,004 shares — an estimated $359K sold.

Ergoteles first reported a position in CDTX in Q2 2021 and held it in 2 quarters. The position peaked at $359K in Q3 2021. 52 funds tracked by Wall St. Rank hold CDTX as of Q4 2021.

  • Ergoteles reported no remaining Cidara Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Ergoteles sold 8,004 Cidara Therapeutics shares in Q4 2021, an estimated $359K.
  • Ergoteles first reported a position in Cidara Therapeutics in Q2 2021 and held it in 2 quarters.
  • Ergoteles's Cidara Therapeutics position peaked at $359K in Q3 2021.
  • 52 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2021.

Based on Ergoteles's 13F filing for Q4 2021, filed 14 Feb 2022.